Osteoarthritis (OA) represents one of the most prevalent degenerative joint disorders globally, imposing substantial socioeconomic burdens on aging populations. This debilitating condition is pathologically characterized by progressive articular cartilage degradation, aberrant subchondral bone remodeling, and persistent macrophage-driven inflammatory cascades that collectively compromise joint integrity and function. Despite extensive research efforts, contemporary clinical interventions remain predominantly palliative, focusing on symptomatic pain relief rather than disease modification. The absence of effective pharmaceutical agents capable of halting or reversing cartilage destruction stems fundamentally from incomplete elucidation of OA's intricate pathophysiological network involving mechanical, biological, and biochemical factors.

Traditional Chinese medicine (TCM) has accumulated substantial empirical knowledge regarding OA management over millennia of clinical practice. San-miao-San, a classical TCM formulation, has demonstrated notable efficacy in treating inflammatory arthropathies, with Huangbai serving as its principal ingredient. Magnoflorine, a bioactive benzylisoquinoline alkaloid isolated from Huangbai, exhibits potent anti-inflammatory and antioxidant pharmacological properties. However, the precise molecular mechanisms underlying magnoflorine's therapeutic potential in OA pathogenesis, particularly its interactions with specific cellular targets and signaling pathways, remain inadequately characterized. Consequently, this study was designed to systematically investigate the molecular basis of magnoflorine's protective effects against OA progression.

We established a surgically-induced OA model in Sprague-Dawley rats through destabilization of the medial meniscus (DMM), followed by intra-articular administration of magnoflorine. Therapeutic efficacy was comprehensively evaluated utilizing micro-computed tomography (micro-CT) for bone architectural analysis, histopathological staining (Safranin-O/Fast Green, Hematoxylin-Eosin), immunohistochemistry, and immunofluorescence microscopy. Our results demonstrated that magnoflorine treatment significantly ameliorated joint degeneration, stabilized subchondral bone microstructure, restored trabecular bone parameters, enhanced cartilage morphology and extracellular matrix synthesis, and modulated expression of osteogenesis-related biomarkers. Furthermore, magnoflorine effectively suppressed pro-inflammatory M1 macrophage polarization while concomitantly promoting anti-inflammatory M2 phenotype conversion, accompanied by elevated systemic antioxidant enzyme activities in serum.

In vitro investigations revealed that magnoflorine maintained excellent biocompatibility within the concentration range of 25-100 μg/ml, effectively restoring cellular viability under pathological conditions, enhancing MC3T3-E1 preosteoblast migratory capacity, and attenuating oxidative stress damage. Notably, magnoflorine successfully reversed the inhibitory effects of osteoclast-conditioned medium on osteogenic differentiation processes. Mechanistic studies identified reactive oxygen species (ROS) as the central regulatory hub of magnoflorine's therapeutic action. Specifically, ROS suppression sequentially attenuated MAPK and NF-κB pathway activation to inhibit M1 macrophage polarization, while simultaneously activating Nrf2-mediated antioxidant defense systems. These coordinated events ultimately restored osteogenic differentiation through downstream BMP2/SMAD signaling pathway activation.

These comprehensive findings position magnoflorine as a promising disease-modifying therapeutic candidate for OA treatment, bridging traditional herbal medicine with modern molecular pharmacology and providing robust experimental evidence for the scientific rationalization of TCM in contemporary clinical practice.